Department of Japanese Oriental Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Evid Based Complement Alternat Med. 2011;2011:592791. doi: 10.1155/2011/592791. Epub 2011 May 16.
We evaluated the effect of kigikenchuto (KKT), a traditional Japanese formula, in a modified rat pressure-loading skin ulcer model. Rats were divided into three groups, KKT extract orally administered (250 or 500 mg/kg/day for 35 days) and control. KKT shortened the duration until healing. Immunohistochemically, KKT increased CD-31-positive vessels in early phase and increased α-smooth muscle actin-(α-SMA-) positive fibroblastic cells in early phase and decreased them in late phase of wound healing. By Western blotting, KKT showed the potential to decrease inflammatory cytokines (MCP-1, IL-1β, and TNF-α) in early phase, decrease vascular endothelial growth factor in early phase and increase it in late phase, and modulate the expression of extracellular protein matrix (α-SMA, TGF-β1, bFGF, collagen III, and collagen I). These results suggested the possibility that KKT accelerates pressure ulcer healing through decreases of inflammatory cytokines, increase of angiogenesis, and induction of extracellular matrix remodeling.
我们评估了日本传统方剂奇吉肯卓(KKT)在改良的大鼠加压性皮肤溃疡模型中的作用。大鼠分为 KKT 提取物口服给药组(250 或 500mg/kg/天,共 35 天)和对照组。KKT 缩短了愈合时间。免疫组织化学染色显示,KKT 在早期增加了 CD-31 阳性血管,在早期和晚期增加了α-平滑肌肌动蛋白(α-SMA-)阳性成纤维细胞,减少了晚期的成纤维细胞。通过 Western blot 分析,KKT 显示出在早期降低炎症细胞因子(MCP-1、IL-1β 和 TNF-α)、在早期降低血管内皮生长因子(VEGF)和在晚期增加 VEGF 的潜力,并调节细胞外蛋白基质(α-SMA、TGF-β1、bFGF、III 型胶原和 I 型胶原)的表达。这些结果表明,KKT 通过降低炎症细胞因子、增加血管生成和诱导细胞外基质重塑,加速压疮愈合的可能性。